Prelude Historical Balance Sheet

PRLD Stock

USD 1.19 0.04 3.48%

Trend analysis of Prelude Therapeutics balance sheet accounts such as Other Liabilities of 4.1 M, Net Tangible Assets of 136.7 M, Property Plant And Equipment Net of 45.6 M or Accounts Payable of 4.8 M provides information on Prelude Therapeutics' total assets, liabilities, and equity, which is the actual value of Prelude Therapeutics to its prevalent stockholders. By breaking down trends over time using Prelude Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Prelude Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Prelude Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

About Prelude Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Prelude Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Prelude Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Prelude Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Prelude currently owns. An asset can also be divided into two categories, current and non-current.

Prelude Therapeutics Balance Sheet Chart

At present, Prelude Therapeutics' Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 45.6 M, whereas Total Current Liabilities is forecasted to decline to about 14.9 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Total Assets

Total assets refers to the total amount of Prelude Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Prelude Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Prelude Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Prelude Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Prelude Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Prelude Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prelude Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.At present, Prelude Therapeutics' Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 45.6 M, whereas Total Current Liabilities is forecasted to decline to about 14.9 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	11.3M	15.8M	18.1M	19.0M
Total Assets	220.5M	277.7M	319.3M	195.3M

Other Current Liab Total Assets

Prelude Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital	Property Plant Equipment	Short Long Term Debt Total	Other Current Assets	Short Term Debt
Total Assets		0.87	0.97	1.0	0.87	0.98	0.69	-0.26	-0.88	0.93	0.37	0.74	1.0	0.93	-0.8	0.88	-0.54	1.0	0.68	1.0	0.87	0.99	0.9	0.68	0.79	0.85
Other Current Liab	0.87		0.9	0.85	0.92	0.8	0.93	-0.04	-0.97	0.77	0.21	0.96	0.85	0.92	-0.64	0.97	-0.34	0.85	0.93	0.85	0.92	0.84	0.97	0.92	0.54	0.67
Total Current Liabilities	0.97	0.9		0.95	0.93	0.93	0.73	-0.09	-0.94	0.92	0.2	0.8	0.95	0.95	-0.73	0.92	-0.41	0.95	0.73	0.95	0.93	0.94	0.95	0.71	0.65	0.79
Total Stockholder Equity	1.0	0.85	0.95		0.85	0.99	0.65	-0.31	-0.85	0.93	0.41	0.7	1.0	0.9	-0.85	0.86	-0.61	1.0	0.64	1.0	0.85	1.0	0.88	0.64	0.81	0.87
Other Liab	0.87	0.92	0.93	0.85		0.82	0.82	0.17	-0.96	0.88	-0.03	0.88	0.85	0.87	-0.64	0.98	-0.36	0.85	0.82	0.85	1.0	0.84	0.98	0.8	0.61	0.69
Net Tangible Assets	0.98	0.8	0.93	0.99	0.82		0.58	-0.36	-0.81	0.94	0.45	0.64	0.99	0.85	-0.87	0.82	-0.66	0.99	0.57	0.99	0.82	0.99	0.85	0.57	0.85	0.91
Property Plant And Equipment Net	0.69	0.93	0.73	0.65	0.82	0.58		0.17	-0.89	0.52	0.01	0.99	0.65	0.85	-0.4	0.9	-0.13	0.65	1.0	0.65	0.82	0.64	0.85	1.0	0.33	0.36
Net Debt	-0.26	-0.04	-0.09	-0.31	0.17	-0.36	0.17		-0.06	-0.16	-0.98	0.17	-0.31	-0.07	0.48	0.1	0.55	-0.31	0.17	-0.31	0.17	-0.33	0.04	0.14	-0.42	-0.5
Retained Earnings	-0.88	-0.97	-0.94	-0.85	-0.96	-0.81	-0.89	-0.06		-0.81	-0.09	-0.93	-0.85	-0.93	0.63	-0.98	0.3	-0.85	-0.88	-0.85	-0.95	-0.84	-0.98	-0.87	-0.51	-0.66
Accounts Payable	0.93	0.77	0.92	0.93	0.88	0.94	0.52	-0.16	-0.81		0.25	0.61	0.94	0.77	-0.77	0.83	-0.55	0.93	0.52	0.94	0.88	0.94	0.88	0.5	0.83	0.91
Cash	0.37	0.21	0.2	0.41	-0.03	0.45	0.01	-0.98	-0.09	0.25		0.0	0.41	0.19	-0.55	0.05	-0.59	0.41	0.0	0.41	-0.03	0.43	0.11	0.03	0.48	0.58
Non Current Assets Total	0.74	0.96	0.8	0.7	0.88	0.64	0.99	0.17	-0.93	0.61	0.0		0.7	0.88	-0.46	0.94	-0.18	0.7	0.99	0.7	0.88	0.69	0.91	0.99	0.37	0.44
Cash And Short Term Investments	1.0	0.85	0.95	1.0	0.85	0.99	0.65	-0.31	-0.85	0.94	0.41	0.7		0.9	-0.83	0.85	-0.59	1.0	0.64	1.0	0.85	1.0	0.88	0.64	0.83	0.88
Common Stock Shares Outstanding	0.93	0.92	0.95	0.9	0.87	0.85	0.85	-0.07	-0.93	0.77	0.19	0.88	0.9		-0.65	0.91	-0.33	0.9	0.84	0.9	0.87	0.89	0.9	0.84	0.54	0.62
Non Current Liabilities Total	-0.8	-0.64	-0.73	-0.85	-0.64	-0.87	-0.4	0.48	0.63	-0.77	-0.55	-0.46	-0.83	-0.65		-0.66	0.91	-0.85	-0.39	-0.82	-0.64	-0.83	-0.66	-0.39	-0.72	-0.88
Other Stockholder Equity	0.88	0.97	0.92	0.86	0.98	0.82	0.9	0.1	-0.98	0.83	0.05	0.94	0.85	0.91	-0.66		-0.38	0.86	0.89	0.85	0.98	0.85	0.99	0.88	0.58	0.67
Total Liab	-0.54	-0.34	-0.41	-0.61	-0.36	-0.66	-0.13	0.55	0.3	-0.55	-0.59	-0.18	-0.59	-0.33	0.91	-0.38		-0.61	-0.13	-0.59	-0.36	-0.6	-0.37	-0.13	-0.68	-0.74
Net Invested Capital	1.0	0.85	0.95	1.0	0.85	0.99	0.65	-0.31	-0.85	0.93	0.41	0.7	1.0	0.9	-0.85	0.86	-0.61		0.64	1.0	0.85	1.0	0.88	0.64	0.81	0.87
Property Plant And Equipment Gross	0.68	0.93	0.73	0.64	0.82	0.57	1.0	0.17	-0.88	0.52	0.0	0.99	0.64	0.84	-0.39	0.89	-0.13	0.64		0.64	0.82	0.63	0.85	1.0	0.32	0.35
Total Current Assets	1.0	0.85	0.95	1.0	0.85	0.99	0.65	-0.31	-0.85	0.94	0.41	0.7	1.0	0.9	-0.82	0.85	-0.59	1.0	0.64		0.85	1.0	0.88	0.64	0.83	0.88
Non Current Liabilities Other	0.87	0.92	0.93	0.85	1.0	0.82	0.82	0.17	-0.95	0.88	-0.03	0.88	0.85	0.87	-0.64	0.98	-0.36	0.85	0.82	0.85		0.84	0.98	0.8	0.61	0.69
Net Working Capital	0.99	0.84	0.94	1.0	0.84	0.99	0.64	-0.33	-0.84	0.94	0.43	0.69	1.0	0.89	-0.83	0.85	-0.6	1.0	0.63	1.0	0.84		0.87	0.63	0.84	0.88
Property Plant Equipment	0.9	0.97	0.95	0.88	0.98	0.85	0.85	0.04	-0.98	0.88	0.11	0.91	0.88	0.9	-0.66	0.99	-0.37	0.88	0.85	0.88	0.98	0.87		0.83	0.62	0.74
Short Long Term Debt Total	0.68	0.92	0.71	0.64	0.8	0.57	1.0	0.14	-0.87	0.5	0.03	0.99	0.64	0.84	-0.39	0.88	-0.13	0.64	1.0	0.64	0.8	0.63	0.83		0.32	0.34
Other Current Assets	0.79	0.54	0.65	0.81	0.61	0.85	0.33	-0.42	-0.51	0.83	0.48	0.37	0.83	0.54	-0.72	0.58	-0.68	0.81	0.32	0.83	0.61	0.84	0.62	0.32		0.85
Short Term Debt	0.85	0.67	0.79	0.87	0.69	0.91	0.36	-0.5	-0.66	0.91	0.58	0.44	0.88	0.62	-0.88	0.67	-0.74	0.87	0.35	0.88	0.69	0.88	0.74	0.34	0.85

Click cells to compare fundamentals

Prelude Therapeutics Account Relationship Matchups

Prelude Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	223.6M	305.1M	220.5M	277.7M	319.3M	195.3M
Other Current Liab	7.5M	7.9M	11.3M	15.8M	18.1M	19.0M
Total Current Liabilities	11.4M	19.2M	21.7M	21.8M	25.1M	14.9M
Total Stockholder Equity	212.2M	285.9M	195.4M	237.1M	272.7M	157.4M
Net Tangible Assets	(49.4M)	212.2M	285.9M	195.4M	224.8M	136.7M
Property Plant And Equipment Net	2.5M	5.6M	6.7M	37.7M	43.4M	45.6M
Net Debt	(218.3M)	(30.1M)	(28.8M)	(8.4M)	(9.7M)	(10.1M)
Retained Earnings	(107.4M)	(219.1M)	(334.6M)	(456.4M)	(410.8M)	(390.2M)
Accounts Payable	3.9M	7.8M	6.8M	4.6M	5.3M	4.8M
Cash	218.3M	31.8M	30.6M	25.3M	22.8M	45.4M
Non Current Assets Total	2.8M	10.0M	16.1M	42.1M	48.4M	50.8M
Cash And Short Term Investments	218.3M	291.2M	201.7M	232.9M	267.9M	179.4M
Common Stock Shares Outstanding	43.7M	47.6M	47.4M	60.4M	69.4M	48.3M
Liabilities And Stockholders Equity	223.6M	305.1M	220.5M	277.7M	319.3M	195.3M
Non Current Liabilities Total	32K	9.6M	3.4M	18.7M	16.9M	18.0M
Other Stockholder Equity	96.0M	505.7M	531.7M	693.3M	797.2M	837.1M
Total Liab	11.4M	19.2M	25.1M	40.6M	36.5M	27.6M
Net Invested Capital	212.2M	285.9M	195.4M	237.1M	272.7M	157.4M
Property Plant And Equipment Gross	2.5M	5.6M	6.7M	41.3M	47.5M	49.9M
Total Current Assets	220.8M	295.1M	204.4M	235.6M	270.9M	181.8M
Accumulated Other Comprehensive Income	(223.6M)	(711K)	(1.7M)	223K	256.5K	269.3K
Non Current Liabilities Other	5K	32K	3.4M	3.3M	3.8M	4.0M
Net Working Capital	209.4M	275.9M	182.7M	213.8M	245.8M	166.9M
Property Plant Equipment	1.6M	2.5M	5.6M	6.7M	7.7M	8.1M
Other Current Assets	5M	7.8M	2.7M	2.7M	3.1M	4.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:

How To Invest In Prelude

Details

Is Prelude Stock a good investment?

Details

What is Prelude Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.77)

Revenue Per Share

0.04

Return On Assets

(0.39)

Return On Equity

(0.67)

The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Prelude Historical Balance Sheet

About Prelude Balance Sheet Analysis

Prelude Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Prelude Therapeutics balance sheet Correlations

Prelude Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Prelude Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity

Property Plant Equipment	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.96	Other Liab
Non Current Liabilities Other	- 0.95	Retained Earnings